Find recruiting clinical trials for pancreatic cancer in the UK — from surgical adjuvant therapy to FOLFIRINOX and targeted treatments. See where trials fit into your treatment pathway.
Free to use · Live data from ClinicalTrials.gov · Updated daily
See where clinical trials fit into your treatment journey
For the ~15% diagnosed early enough for surgery, followed by chemotherapy to reduce recurrence risk
Standard: Whipple procedure (pancreaticoduodenectomy) followed by modified FOLFIRINOX or gemcitabine
Chemotherapy (sometimes with radiation) to shrink the tumour before surgery
Standard: FOLFIRINOX or gemcitabine/nab-paclitaxel for 2-4 months before reassessing for surgery
Tumours that can't be surgically removed but haven't spread distantly
Standard: FOLFIRINOX or gemcitabine/nab-paclitaxel; some centres add stereotactic radiotherapy
For widespread disease, trials explore immunotherapy, targeted therapy, and new drug combinations
Emerging: KRAS G12C inhibitors, PARP inhibitors (for BRCA-mutated), immunotherapy combinations, and stroma-modulating agents
Pancreatic cancer affects about 10,500 people per year in the UK. It's one of the hardest cancers to treat — only about 25% survive one year and 7% survive five years. Symptoms often appear late: jaundice, back pain, unexplained weight loss, and new-onset diabetes.
Pancreatic cancer has seen the smallest improvement in survival of any cancer over the past 50 years. Only 1 in 10 patients currently joins a trial. New approaches — KRAS-targeted drugs, immunotherapy combinations, and early detection strategies — could transform outcomes.
About 90% of pancreatic cancers carry KRAS mutations (most commonly G12D or G12V). New KRAS G12C inhibitors are showing promise in early trials. Molecular profiling of your tumour can identify targeted therapy options — ask your oncologist about genomic testing.
Loading trials from ClinicalTrials.gov...